Paris (France), 18 January 2019 \u2013 <\/b>Ipsen (Euronext: IPN; ADR: IPSEY) today presents at TOXINS, results from an international survey revealing the hidden burden of spasticity and the need for longer periods of symptomatic relief1. Affecting 12 million people around the world2, spasticity is one of the most common and disabling conditions associated with neurological diseases in adults (stroke, traumatic brain, etc.) and characterised by an abnormal increase in muscle tone or stiffness3. A survey of 615 respondents from 6 participating countries confirms that spasticity has a profound impact on ability to perform everyday tasks, including the ability to carry items, walk, and drive and reduces independence overall.
\nThe survey1 also found that spasticity affects the ability to work (22% of patients surveyed did not work) and impacts sex life as well as self-esteem. For 94% of patients surveyed, satisfaction with life improves with botulinum toxin type A treatment \u2013 injection of BoNT-A is one of the reference treatments for spasticity that acts by blocking neuromuscular transmission4.
\nAlexandre Lebeaut, M.D., Executive Vice President, Research & Development and Chief Scientific Officer, Ipsen<\/b>stated: \u201cSpasticity is not always the first symptom that is managed in adult or children central nervous system insult, but it has a long term and chronic profound impact on fundamental aspects of patients and caregivers\u2019 daily lives. The hallmark of good patient care is <\/em>providing access to effective treatments that can control symptoms, and improve quality of life<\/em>\u201d.<\/em>
\nThe survey1, undertaken in association with Carenity, a social media platform for people living with chronic diseases, also exposes the practical issues related to spasticity and its treatment. Most patients (78%) have to take time off work because of their condition. Treatment also represents a financial burden with average out-of-pocket expenses of 150 Euros per injection. 9 out of 10 respondents want long periods without symptoms, and expect it would have a positive impact on their quality of life. An interim analysis of ULIS-III5 \u2013 a phase IV study on attainment of person-centered goals after BoNT-A treatment for adult upper limb spasticity \u2013 reporting on treatment intervals is presented at TOXINS 2019.
\nJorge Jacinto, PM&R Senior Consultant, Head of Department of Adult Neuro-rehabilitation, Centro de Medicina de Reabilita\u00e7\u00e3o de Alcoit\u00e3o, Portugal, <\/b>concluded: \u201cThe Carenity survey as well as observational studies like ULIS-III<\/em>5 provide priceless patients insights to clinicians. It will allow us to not only consider the burden of spasticity in its entirety, but also rethink the treatment paradigm to improve patients\u2019 and caregivers\u2019 quality of life.\u201d<\/em>
\nIpsen will be presenting the results of this survey as part of 50 posters submitted to TOXINS 2019 in Copenhagen, which include:<\/p>\n
<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[1763,149],"tags":[],"class_list":["post-36896","press_release","type-press_release","status-publish","hentry","category-corporate-pressrelease","category-pressrelease","entry"],"acf":[],"yoast_head":"\n